

## NOTICE OF DETERMINATION CHANGE IN RECOGNISED LEGAL REPRESENTATIVE MODULE 4 - MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA)

- On 17 July 2023, I designated the Medicines and Healthcare products Regulatory Agency (MHRA) as a Core Participant in Module 4. At the same time, I designated Catherine Brydges of the Government Legal Department as its qualified lawyer in relation to Module 4.
- 2. On 15 August 2023, the Inquiry was informed that Cartherine Brydges was leaving the Government Legal Department and that James McArthur would be acting as the MHRA's legal representative in relation to Module 4. On 23 August 2023 I designated James McArthur as MHRA's recognised legal representative in Module 4 in accordance with Rule 6(1) of the Inquiry Rules 2006.
- 3. On 19 March 2024, the Inquiry was informed that, due to staff changes, Georgia Tate would be acting as the MHRA's legal representative in relation to Module 4.
- 4. Accordingly, as I am satisfied that the MHRA has appointed Georgia Tate as its qualified lawyer, I designate Georgia Tate as its recognised legal representative in Module 4 in accordance with Rule 6(1) of the Inquiry Rules 2006.

Rt Hon Baroness Heather Hallett DBE
Chair of the UK Covid-19 Inquiry
21 March 2024